AI Article Synopsis
- - The text discusses a new theranostic platform that combines biocompatibility, targeting, imaging, and therapy for cancer treatment using hybrid nanoparticles made of fullerene and gold (FGNPs).
- - FGNPs demonstrate superior photoacoustic signals and photothermal effects when exposed to optimal light, making them effective for imaging and killing cancer cells in laboratory studies.
- - The nanoparticles can accumulate in tumor tissue, allowing for better visualization through imaging techniques in mouse models, indicating their potential for improving cancer diagnosis and therapy.
Article Abstract
Developing photoactivatable theranostic platforms with integrated functionalities of biocompatibility, targeting, imaging contrast, and therapy is a promising approach for cancer diagnosis and therapy. Here, we report a theranostic agent based on a hybrid nanoparticle comprising fullerene nanocrystals and gold nanoparticles (FGNPs) for photoacoustic imaging and photothermal therapy. Compared to gold nanoparticles and fullerene crystals, FGNPs exhibited stronger photoacoustic signals and photothermal heating characteristics by irradiating light with an optimal wavelength. Our studies demonstrated that FGNPs could kill cancer cells due to their photothermal heating characteristics in vitro. Moreover, FGNPs that are accumulated in tumor tissue via the enhanced permeation and retention effect can visualize tumor tissue due to their photoacoustic signal in tumor xenograft model mice. The theranostic agent with FGNPs shows promise for cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105889 | PMC |
| http://dx.doi.org/10.3390/ijms23094686 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
Blood
January 2025
Stanford University Medical Center, Stanford, California, United States.
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies enrichment of donor regulatory T cells (Tregs) appears to prevent GVHD and promote healthy immunity.We enrolled 44 patients on an open-label, single-center, phase 2 efficacy study investigating if a precision selected and highly purified Treg cell therapy manufactured from donor mobilized peripheral blood improves one-year GVHD-free relapse free survival (GRFS) after myeloablative conditioning (trial NCT01660607).
View Article and Find Full Text PDFRetrospective analysis of clinical characteristics and treatment differences between severe and non-severe neonatal types of pneumonia with RSV infection.
Medicine (Baltimore)
January 2025
Precision Medical Center, Wuhan Childrens Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China.
Understanding the differences between children with severe and non-severe types of neonatal pneumonia is crucial for clinical treatment and disease management. In this study, we retrospectively analyzed the clinical data of infants with neonatal pneumonia diagnosed as respiratory syncytial virus infection at Wuhan Children's Hospital between December 1, 2022 and November 30, 2023. Further, the recruited subjects were categorized into severe and non-severe groups based on the severity score.
View Article and Find Full Text PDFProteomic patterns associated with ketamine response in major depressive disorders.
Cell Biol Toxicol
January 2025
Research Institute, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, 510370, China.
Background: Major depressive disorder (MDD) is characterized by persistent feelings of sadness and loss of interest. Ketamine has been widely used to treat MDD owing to its rapid effect in relieving depressive symptoms. Importantly, not all patients respond to ketamine treatment.
View Article and Find Full Text PDFExploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives.
ACS Appl Bio Mater
January 2025
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India.
Immunotherapy is a cutting-edge approach that leverages sophisticated technology to target tumor-specific antibodies and modulate the immune system to eradicate cancer and enhance patients' quality of life. Bioinformatics and genetic science advancements have made it possible to diagnose and treat cancer patients using immunotherapy technology. However, current immunotherapies against cancer have limited clinical benefits due to cancer-associated antigens, which often fail to interact with immune cells and exhibit insufficient therapeutic targeting with unintended side effects.
View Article and Find Full Text PDFMultifunctional theranostic glyconanoprobes for synergistic eradication of breast cancer.
J Mater Chem B
January 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, 34093, Istanbul, Turkey.
Theranostic agents hold great promise for personalized medicine by combining diagnostic and therapeutic functions. Herein, two novel multifunctional theranostic glyconanoprobes targeting breast cancer were engineered for synergistic dual chemo-gene therapy and triple chemo-gene-photothermal therapy. Upconversion nanoparticles (UCNPs) were prepared and coated with a Dox-loaded glycopeptide polymer (P-Dox) to form UCNP@P-Dox for improving stability.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!